Recently we have received notifications from the Board of Pharmacy from several States regarding the compounding of semaglutide.   Semaglutide is a commercially available drug product marketed as Ozempic for treating diabetes and Wegovy for weight loss.   These notification/warnings are a reminder that semaglutide is currently prohibited from being compounded.

The warning from the federal Food Drug & Cosmetic Act prohibits pharmacies from compounding “drug products that are essentially copies of a commercially available drug product.”   In general, compounding pharmacies may not compound semaglutide, a commercially available drug product.

Any compounding pharmacies or prescribers that violate this governing law may lead to enforcement action by the Food and Drug Administration and the Board of Pharmacy.  In addition, the pharmaceutical manufacturers may initiate legal proceedings against prescribers and compounders to combat illegal semaglutide drug product compounding.

Many of our customers may have already received this warning from their Board of Pharmacy, but we just wanted to let you know in case you had not heard this news. Please call us if you have any questions.